

Table I-17
US PREVALENCE COUNTS, INVASIVE CANCERS ONLY, JANUARY 1, 2003^a
USING DIFFERENT TUMOR INCLUSION CRITERIA^b

Site/Sex	5-Year Limited Duration			28-year Limited Duration	
	1st Invasive Tumor Ever ^c	1st Per Site in Previous 28 Years ^d	1st Per Site in Previous 5 Years ^e	1st Invasive Tumor Ever ^c	1st Per Site in Previous 28 Years ^d
All Sites	3,962,252	4,035,862	4,346,625	9,822,273	9,999,566
Male	2,012,274	2,038,895	2,188,678	4,554,140	4,605,294
Female	1,949,978	1,996,967	2,157,947	5,268,133	5,394,272
Oral Cavity & Pharynx	83,955	95,507	98,496	215,563	235,425
Male	55,821	62,933	64,786	138,069	149,462
Female	28,134	32,574	33,710	77,494	85,963
Esophagus	16,590	19,648	19,648	23,825	27,849
Male	12,747	14,965	14,965	17,985	20,779
Female	3,843	4,683	4,683	5,840	7,070
Stomach	29,257	34,386	34,531	57,098	64,641
Male	17,694	20,964	21,014	32,717	37,242
Female	11,563	13,422	13,517	24,381	27,399
Colon & Rectum	416,089	476,844	484,622	1,012,722	1,122,054
Male	207,662	239,032	242,507	494,463	544,591
Female	208,427	237,812	242,115	518,259	577,463
Liver & Intrahep	12,879	14,747	14,747	16,970	19,172
Male	8,577	9,821	9,821	10,783	12,211
Female	4,302	4,926	4,926	6,187	6,961
Pancreas	20,647	24,183	24,183	27,201	31,313
Male	10,136	11,859	11,859	13,101	15,030
Female	10,511	12,324	12,324	14,100	16,283
Larynx	33,012	37,952	38,189	91,949	100,525
Male	26,366	30,377	30,556	73,689	80,335
Female	6,646	7,575	7,633	18,260	20,190
Lung & Bronchus	204,290	249,735	253,884	340,934	404,089
Male	99,565	122,836	124,721	165,339	195,671
Female	104,725	126,899	129,163	175,595	208,418
Melanoma of the Skin	210,287	231,918	238,857	612,953	652,573
Male	111,633	124,847	129,353	303,073	325,161
Female	98,654	107,071	109,504	309,880	327,412
Breast					
Female	822,609	880,184	918,327	2,236,730	2,370,054
Cervix					
Female	43,374	45,413	45,468	183,935	189,267
Corpus & Uterus					
Female	144,051	161,434	161,482	493,698	532,684
Ovary ^f					
Female	54,837	62,770	62,781	145,849	162,935

^a US 2003 cancer prevalence counts are based on 2003 cancer prevalence proportions from the SEER 9 registries and 1/1/2003 US population estimates based on the average of 2002 and 2003 population estimates from the US Bureau of the Census.

^{bcd} (b) Prevalence estimates are ambiguous for those with multiple cancers, unless the tumor inclusion criteria are understood. Depending on the application, different inclusion criteria may be appropriate. This table provides three different methods of tumor inclusion: (c) First invasive tumor ever; (d) First invasive tumor for each cancer site diagnosed during the previous 28 years (1975-2002); (e) First invasive tumor for each cancer site diagnosed during the previous 5 years (1998-2002). For definitions (d) and (e) all sites is treated as a separate cancer "site".

Consider a woman who had three invasive cancers: Melanoma in 1981; Breast cancer in 1998; Melanoma in 1999.

In method (c) the melanoma is the woman's first cancer, and is counted for the melanoma and all sites 28-year limited duration prevalence. For 5-year limited duration prevalence, the woman is not counted at all since her first cancer occurred more than 5 years prior to 1/1/2003.

In method (d) the 1981 melanoma is counted for the melanoma and all sites 28-year limited duration prevalence. The 1998 breast cancer is counted for the breast 5-year and 28-year limited duration prevalence.

In method (e) the 1998 breast cancer is counted for the breast cancer and all sites 5-year limited duration prevalence. The 1999 melanoma is counted for 5-year limited duration prevalence for melanoma.

^f Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

Table I-17 - continued
US PREVALENCE COUNTS, INVASIVE CANCERS ONLY, JANUARY 1, 2003^a
USING DIFFERENT TUMOR INCLUSION CRITERIA^b

Site/Sex	5-Year Limited Duration			28-year Limited Duration	
	1st Invasive Tumor Ever ^c	1st Per Site in Previous 28 Years ^d	1st Per Site in Previous 5 Years ^e	1st Invasive Tumor Ever ^c	1st Per Site in Previous 28 Years ^d
Prostate					
Male	925,708	996,736	996,805	1,932,939	2,062,326
Testis					
Male	38,559	39,095	39,651	151,951	153,792
Urinary Bladder					
Male	184,975	224,084	226,601	480,880	548,618
Female	138,238	167,628	169,644	356,081	405,065
Female	46,737	56,456	56,957	124,799	143,553
Kidney & Renal Pelvis					
Male	94,596	113,883	114,668	218,509	250,873
Female	56,984	69,698	70,246	129,547	149,743
Female	37,612	44,185	44,422	88,962	101,130
Brain & Nervous System					
Male	37,131	38,985	39,154	96,508	99,298
Female	19,885	20,784	20,884	51,982	53,322
Female	17,246	18,201	18,270	44,526	45,976
Thyroid					
Male	96,001	103,049	103,251	300,771	315,293
Female	22,362	24,688	24,716	68,236	72,272
Female	73,639	78,361	78,535	232,535	243,021
Hodgkin Lymphoma					
Male	33,724	35,148	35,183	131,045	133,819
Female	17,816	18,650	18,661	68,125	69,654
Female	15,908	16,498	16,522	62,920	64,165
Non-Hodgkin Lymphoma					
Male	159,781	181,551	182,318	350,868	385,654
Female	83,817	95,629	96,015	182,423	199,759
Female	75,964	85,922	86,303	168,445	185,895
Myeloma					
Male	35,577	41,051	41,074	51,578	58,336
Female	19,965	23,210	23,233	28,677	32,603
Female	15,612	17,841	17,841	22,901	25,733
Leukemia					
Male	82,812	92,941	93,009	192,632	208,020
Female	48,279	54,323	54,357	109,292	118,067
Female	34,533	38,618	38,652	83,340	89,953
Acute Lymphocytic Leuk					
Male	13,967	14,109	14,109	47,535	47,775
Female	7,952	8,004	8,004	26,215	26,299
Female	6,015	6,105	6,105	21,320	21,476
Childhood (0-19)					
Male	57,723	57,832	58,156	227,872	228,339
Female	30,378	30,418	30,580	117,016	117,217
Female	27,345	27,414	27,576	110,856	111,122
Kaposi's Sarcoma					
Male	6,714	7,243	7,267	20,047	20,990
Female	6,074	6,548	6,572	18,586	19,429
Female	640	695	695	1,461	1,561
Mesothelioma					
Male	2,802	3,396	3,396	4,182	4,870
Female	1,903	2,363	2,363	2,438	2,958
Female	899	1,033	1,033	1,744	1,912

^a US 2003 cancer prevalence counts are based on 2003 cancer prevalence proportions from the SEER 9 registries and 1/1/2003 US population estimates based on the average of 2002 and 2003 population estimates from the US Bureau of the Census.

^{bcde} (b) Prevalence estimates are ambiguous for those with multiple cancers, unless the tumor inclusion criteria are understood. Depending on the application, different inclusion criteria may be appropriate. This table provides three different methods of tumor inclusion: (c) First invasive tumor ever; (d) First invasive tumor for each cancer site diagnosed during the previous 28 years (1975-2002); (e) First invasive tumor for each cancer site diagnosed during the previous 5 years (1998-2002). For definitions (d) and (e) all sites is treated as a separate cancer "site".

Consider a woman who had three invasive cancers: Melanoma in 1981; Breast cancer in 1998; Melanoma in 1999.

In method (c) the melanoma is the woman's first cancer, and is counted for the melanoma and all sites 28-year limited duration prevalence. For 5-year limited duration prevalence, the woman is not counted at all since her first cancer occurred more than 5 years prior to 1/1/2003.

In method (d) the 1981 melanoma is counted for the melanoma and all sites 28-year limited duration prevalence. The 1998 breast cancer is counted for the breast 5-year and 28-year limited duration prevalence.

In method (e) the 1998 breast cancer is counted for the breast cancer and all sites 5-year limited duration prevalence. The 1999 melanoma is counted for 5-year limited duration prevalence for melanoma.